Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Competency in understanding nature of study and ability to sign informed consent form~* A clinical diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder (manic or mixed) that has been treated with antipsychotics (oral olanzapine, risperidone or quetiapine) for at least 3 months.~* Treatment with any of the antipsychotic medications olanzapine, risperidone, or quetiapine for at least 3 months~* A Clinical Global Impression-Severity Scale score of 4 or lower at baseline~* Confirmed diagnosis of metabolic syndrome~* Patients not receiving treatment specifically for any of the parameters related to metabolic syndrome at the time of randomization~* Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and up to 4 weeks after last dose of investigational product~* Patients for whom it is clinically appropriate to switch from their current atypical antipsychotic to aripiprazole (determined by the investigator)~Exclusion Criteria:~* Risk of suicide (suicidal ideation or recently attempted suicide)~* Meeting Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision criteria for any significant psychoactive substance use disorder within 3 months of screening~* Diagnosis of type 1 or 2 diabetes mellitus~* Current treatment for 1 of the components of metabolic syndrome~* Use of medication for the purpose of weight loss~* Diagnosis of bipolar disorders other than bipolar 1, depression with psychotic symptoms, or organic brain syndromes~* History of neuroleptic malignant syndrome~* Diagnosis of Parkinson's disease, Alzheimer's disease, multiple sclerosis, cerebral palsy, epilepsy, or mental retardation~* History of seizures~* Abnormal blood count for platelets, hemoglobin, absolute neutrophils, aspartate aminotransferase, alanine aminotransferase, creatinine, fasting glucose, and thyroid-stimulating hormone~* Electrocardiogram recording with QTc interval \>475 msec~* Detectable levels of cocaine or positive screen for stimulants or other drugs considered (determined by the investigator) to be of abuse or dependence~* Blood alcohol levels superior or equal to 50 mg/dL \[or 10.9 mmol/L\]~* Prior participation in an aripiprazole clinical trial~* Treatment with aripiprazole within 1 month of enrollment~* Predefined exclusionary laboratory tests~* Patients with Bipolar Disorder treated with adjunctive therapy other than a stable dose of mood stabilizers (lithium or valproate) must undergo a 30-day washout period for adjunctive therapies, such as antidepressants, prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: EXPERIMENTAL): None
- Control group (Oanzapine, risperidone, or quetiapine) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).